Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain

Vortioxetine is a multimodal antidepressant approved for treatment of major depressive disorder. Preclinical studies have demonstrated that the mechanism of action of vortioxetine might be different from selective serotonin reuptake inhibitors (SSRIs), including larger serotonin (5-HT) release and d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropsychopharmacology (New York, N.Y.) N.Y.), 2019-09, Vol.44 (10), p.1706-1713
Hauptverfasser:	Yang, Kai-Chun, Stepanov, Vladimir, Amini, Nahid, Martinsson, Stefan, Takano, Akihiro, Bundgaard, Christoffer, Bang-Andersen, Benny, Sanchez, Connie, Halldin, Christer, Farde, Lars, Finnema, Sjoerd J
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antidepressants Benzopyrans Benzylamines Brain Brain - diagnostic imaging Brain - drug effects Brain - metabolism Citalopram Citalopram - metabolism Citalopram - pharmacology Dorsal raphe nucleus Dorsal Raphe Nucleus - diagnostic imaging Dorsal Raphe Nucleus - drug effects Dorsal Raphe Nucleus - metabolism Dosage Drug development Emission analysis Female Macaca mulatta Morpholines Phenethylamines Piperazines Positron emission tomography Raphe nuclei Receptor, Serotonin, 5-HT1B - metabolism Receptor, Serotonin, 5-HT2A - metabolism Serotonin Serotonin S1 receptors Serotonin S2 receptors Serotonin uptake inhibitors Serotonin Uptake Inhibitors - metabolism Serotonin Uptake Inhibitors - pharmacology Vortioxetine - metabolism Vortioxetine - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!